Taiho Oncology, Inc.
TAS-120
Advanced Cholangiocarcinoma
Countdown
177days
Phase 2 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 2 trial results for TAS-120 in Advanced Cholangiocarcinoma are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT05727176: Phase 2 trial, sponsor Taiho Oncology, Inc., drug TAS-120. Primary completion date 2026-12 (estimated).”